Molecular Formula | C29H44F2N6O2 |
Molar Mass | 546.7 |
Density | 1.23±0.1 g/cm3(Predicted) |
Boling Point | 679.2±65.0 °C(Predicted) |
Solubility | Soluble in DMSO, not in water |
Appearance | Shape powder, color white to beige |
Color | white to beige |
pKa | 10.06±0.20(Predicted) |
Storage Condition | 2-8°C |
Use | UNC0642 is a potent, selective inhibitor of G9a/GLP with improved PK properties. UNC0642 exhibits an in vitro IC50 <15 nM with selectivity > 100-fold over 13 other HMTs and selected representatives of kinases, ion channels, 7TMs, and other epigenetic proteins. In cells, UNC0642 results in a potent reduction of H3K9me2 in MDA MB231 cells with IC50 = 106 nM. |
Target | G9a/GLP |
In vitro study | UNC0642 displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The K i of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in vitro potency for GLP (IC 50 < 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, a pancreatic carcinoma cell line. |
In vivo study | A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642 results in a plasma C max (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr*ng/mL. |
WGK Germany | 3 |
Reference Show more | 1. Liu F, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-8942.2. Wang L, et al. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Cell Death Dis. 2018 Jan 26;9(2):129 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.829 ml | 9.146 ml | 18.292 ml |
5 mM | 0.366 ml | 1.829 ml | 3.658 ml |
10 mM | 0.183 ml | 0.915 ml | 1.829 ml |
5 mM | 0.037 ml | 0.183 ml | 0.366 ml |
biological activity
UNC0642 is an effective and selective lysine methyltransferase G9a and GLP inhibitor, and the IC50 value of inhibiting G9a is less than 2.5 nM.
target
IC50: <2.5 nM (G9a)
in vitro study
UNC0642 displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The K I of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in vitro potency for GLP (IC 50 < 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, a pancreatic carcinoma cell line.
in vivo studies
A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642 results in a plasma C max (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr*ng/mL.
biological activity | UNC0642 is an effective and selective lysine methyltransferase G9a and GLP inhibitor, and the IC50 value of inhibiting G9a is less than 2.5 nM. |
target | IC50: <2.5 nM (G9a) |
in vitro study | UNC0642 displays high in Vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The K I of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in Vitro potency for GLP (IC 50 < 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, A pancreatic carcinoma cell line. |
in vivo study | A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642 results in a plasma C max (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr * ng/mL. |